<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Some types of non-Hodgkin <z:hpo ids='HP_0002665'>lymphomas</z:hpo> cannot be treated by contemporary preparations </plain></SENT>
<SENT sid="1" pm="."><plain>After repeated relapses and chemotherapy moreover damage of bone marrow occurs and further intense <z:chebi fb="0" ids="35610">cytostatic</z:chebi> treatment is not possible </plain></SENT>
<SENT sid="2" pm="."><plain>Monoclonal antibodies against structures on <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cells are an interesting alternative of <z:chebi fb="0" ids="35610">cytostatic</z:chebi> treatment </plain></SENT>
<SENT sid="3" pm="."><plain>In 2000 the authors administered anti CD20 monoclonal antibody (rituximab, Mabthera Roche), 375 mg/m2, on the 1st, 8th, 15th and 22nd day i.v. to a total of 24 patients with relapsing non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>In five patients the relapse developed after high dosage chemotherapy and autologous transplantation of peripheral stem cells </plain></SENT>
<SENT sid="5" pm="."><plain>Treatment was well tolerated with minimal side-effects </plain></SENT>
<SENT sid="6" pm="."><plain>Favourable therapeutic results were recorded in patients with follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (70% of the therapeutic responses), small lymphocyte <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (64% of therapeutic responses) and in patients with a relapse after autologous transplantations (80% of therapeutic responses) </plain></SENT>
<SENT sid="7" pm="."><plain>Anti CD20 monoclonal antibody is a new effective alternative of <z:chebi fb="0" ids="35610">cytostatic</z:chebi> treatment </plain></SENT>
<SENT sid="8" pm="."><plain>Its position in the therapeutic strategy in patients with non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> awaits elaboration </plain></SENT>
</text></document>